Taiho To Acquire Cullinan Oncology's Subsidiary, Cullinan Pearl - M&A Call Transcript
Good day, and welcome to the Cullinan Oncology, Taiho Collaboration Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Chad Messer the Investor Vice President of Investor Relations of Cullinan Oncology. Please go ahead, sir.
Hello, everyone, and thank you all for joining us to discuss our strategic collaboration with Taiho for the joint development and commercialization of CLN-081. My name is Chad Messer, and I'm the Vice President of Investor Relations at Cullinan Oncology.
Before we begin, I would like to remind you all of the safe harbor provisions outlined on Slide 2. During today's presentation, management will be making certain forward-looking statements which are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties, which may cause actual results to differ materially from those contained in such forward-looking statements. These risks are described more fully in the company's filings made with the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |